Baseline patient characteristics at the time of study entry
| . | TRIL (N = 87) . | DLBCL (N = 429) . |
|---|---|---|
| Response to primary treatment | ||
| <1 y | 41 (47) | 180 (42) |
| >1 y | 23 (26) | 116 (27) |
| Refractory to primary treatment, SD PD | 23 (26) | 133 (31) |
| Age (y), median (range) | 56 (31-69) | 55.5 (19-74) |
| >60 | 26 (30) | 130 (30) |
| Bone marrow involvement, yes | 35 (40) | 23 (5) |
| ECOG PS | ||
| 0-1 | 74 (85) | 375 (87) |
| ≥2 | 13 (15) | 54 (13) |
| Disease stage | ||
| I-II | 18 (21) | 144 (34) |
| III-IV | 69 (79) | 285 (66) |
| Number of prior systemic therapies | ||
| 1 | 52 (60) | 429 (100) |
| 2 | 21 (24) | 0 |
| ≥3 | 14 (16) | 0 |
| Prior radiation | 31 (36) | 97 (23) |
| Prior rituximab | 59 (68) | 325 (76) |
| Elevated LDH | 35 (40) | 188 (44) |
| B symptoms | 20 (23) | 153 (36) |
| Extranodal sites | ||
| 0-1 | 66 (76) | 318 (74) |
| ≥2 | 21 (24) | 111 (26) |
| . | TRIL (N = 87) . | DLBCL (N = 429) . |
|---|---|---|
| Response to primary treatment | ||
| <1 y | 41 (47) | 180 (42) |
| >1 y | 23 (26) | 116 (27) |
| Refractory to primary treatment, SD PD | 23 (26) | 133 (31) |
| Age (y), median (range) | 56 (31-69) | 55.5 (19-74) |
| >60 | 26 (30) | 130 (30) |
| Bone marrow involvement, yes | 35 (40) | 23 (5) |
| ECOG PS | ||
| 0-1 | 74 (85) | 375 (87) |
| ≥2 | 13 (15) | 54 (13) |
| Disease stage | ||
| I-II | 18 (21) | 144 (34) |
| III-IV | 69 (79) | 285 (66) |
| Number of prior systemic therapies | ||
| 1 | 52 (60) | 429 (100) |
| 2 | 21 (24) | 0 |
| ≥3 | 14 (16) | 0 |
| Prior radiation | 31 (36) | 97 (23) |
| Prior rituximab | 59 (68) | 325 (76) |
| Elevated LDH | 35 (40) | 188 (44) |
| B symptoms | 20 (23) | 153 (36) |
| Extranodal sites | ||
| 0-1 | 66 (76) | 318 (74) |
| ≥2 | 21 (24) | 111 (26) |
Values are n (%). LDH values were missing in 1 (1.1%) TRIL patient and in 5 (1.2%) DLBCL patients. The presence or absence of B symptoms was not recorded in 4 (4.5%) TRIL patients and 15 (3.5%) DLBCL patients. PD, progressive disease; SD, stable disease.